[Successful 5'-DFUR, CDDP and MMC combination therapy and 5'-DFUR and carboplatin combination therapy for a patient with inoperable advanced gastric cancer with peritonitis carcinomatosa].
A 71-year-old man with Borrmann type 3 gastric cancer and peritonitis carcinomatosa was treated with 5'-DFUR 600 mg/body p.o. daily, CDDP 50-80 mg/m2 i.v. on day 1 and MMC 6 mg/m2 i.v. on day 2 after intraperitoneal injection of CDDP and OK-432. The cycle of CDDP and MMC was repeated every 4 or 5 weeks. After 15 cycles of treatment, the primary gastric lesion disappeared and regional lymph node metastasis was reduced. Because of relapsing of the original lesion and concomitant renal dysfunction, a changed regimen of CDDP and Carboplatin was tried. Then the gastric lesion was reduced and lymph node metastasis disappeared. The patient has lived for about 3 years after diagnosis, but his gastric lesion is gradually worsening with duodenal invasion. This case indicates that these combination chemotherapies are quite promising as an effective treatment for advanced gastric cancer and good quality of patient's life.
Ando
S
S
Dept. of Hematology, Teine Keijinkai Hospital.
Ando
S
S
Katanuma
A
A
Mori
M
M
Tsuji
K
K
Maekubo
H
H
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage; D010538:Peritonitis / Q000209:etiology*; D013274:Stomach Neoplasms / Q000150:complications / Q000188:drug therapy*; D017741:Survivors
D005467:Floxuridine; D016685:Mitomycin; D016190:Carboplatin; D002945:Cisplatin; C025034:doxifluridine